The introduction of the elexacaftor/tezacaftor/ivacaftor combination in therapeutic regimens of CF patients 12 years of age and older with at least 1 F508del mutation, regardless of their second mutation type [120], increased the eligibility for CFTR-modulating treatments to ~90% of CF subjects [121]. Here, CFTR is linked to cystic fibrosis.